{"entity":{"id":"nct03459170","kind":"trial","name":"Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant","aka":[],"tldr":"A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, active and no longer recruiting.","summary":"Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant is a phase 1 interventional study registered as NCT03459170 by Bellicum Pharmaceuticals, with 15 participants planned, started 2018-02-01. Conditions recorded: Hematologic Malignancy. Interventions recorded: BPX-501 T cells and rimiducid.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03459170","url":"https://clinicaltrials.gov/study/NCT03459170"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rivogenlecleucel"],"companies":["bellicum"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03459170","phase":"1","setting":"A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant","sponsor":"Bellicum Pharmaceuticals","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03459170/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rivogenlecleucel","kind":"drug","name":"Rivogenlecleucel","route":"/drugs/rivogenlecleucel/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"}]}}